Treatment of strokes. I.
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D002340:Carotid Artery Diseases / Q000601:surgery; D002533:Cerebral Angiography / Q000009:adverse effects; D002561:Cerebrovascular Disorders / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery / Q000628:therapy*; D003911:Dextrans / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000175:diagnosis / Q000188:drug therapy; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy; D002546:Ischemic Attack, Transient / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D026741:Physical Therapy Modalities; D011379:Prognosis; D014665:Vasodilator Agents / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D003911:Dextrans; D005343:Fibrinolytic Agents; D014665:Vasodilator Agents